Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study

Jeffrey D. Lebensburger, Scott T. Miller, Thomas H. Howard, James F Casella, R. Clark Brown, Ming Lu, Rathi V. Iyer, Sharada Sarnaik, Zora R. Rogers, Winfred C. Wang

Research output: Contribution to journalArticle

Abstract

Background: Clinical complications of sickle cell anemia begin in infancy. BABY HUG (ClinicalTrials.gov, NCT00006400) was a NHLBI-NICHD supported randomized phase III placebo-controlled trial of hydroxyurea (HU) in infants (recruited at 9-18 months) unselected for clinical severity with sickle cell anemia. This secondary analysis of data from BABY HUG examines the influence of anemia on the incidence of sickle cell related complications, and the impact of hydroxyurea therapy in altering these events by comparing children with lower (75th percentile) hemoglobin concentrations at study entry. Procedure: Infants were categorized by: (1) age-adjusted hemoglobin quartiles as determined by higher (Hi) and lower (Lo) hemoglobin concentrations at study entry (9-12 months old: 10.0gm/dL; 12-18 months old: 9.9gm/dL) and (2) treatment arm (hydroxyurea or placebo). Four subgroups were created: placebo (PL) LoHb (n=25), PL HiHb (n=27), hydroxyurea (HU) LoHb (n=21), and HU HiHb (n=18). The primary and secondary endpoints of BABY HUG were analyzed by subgroup. Results: Infants with lower hemoglobin at baseline were more likely to have a higher incidence of clinical events (acute chest syndrome, pain crisis, fever) as well as higher TCD velocities and lower neuropsychological scores at study exit. Hydroxyurea reduced the incidence of these findings. Conclusion: Infants with more severe anemia are at risk for increased clinical events that may be prevented by early initiation of hydroxyurea. Pediatr Blood Cancer 2012;59:675-678.

Original languageEnglish (US)
Pages (from-to)675-678
Number of pages4
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Anemia
Hemoglobins
Placebos
Incidence
Acute Chest Syndrome
National Institute of Child Health and Human Development (U.S.)
National Heart, Lung, and Blood Institute (U.S.)
Chest Pain
Fever
Therapeutics
Neoplasms

Keywords

  • Acute chest syndrome
  • Hydroxyurea
  • Pain
  • Renal
  • Sickle cell anemia
  • Spleen
  • Transcranial doppler

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Influence of severity of anemia on clinical findings in infants with sickle cell anemia : Analyses from the BABY HUG study. / Lebensburger, Jeffrey D.; Miller, Scott T.; Howard, Thomas H.; Casella, James F; Brown, R. Clark; Lu, Ming; Iyer, Rathi V.; Sarnaik, Sharada; Rogers, Zora R.; Wang, Winfred C.

In: Pediatric Blood and Cancer, Vol. 59, No. 4, 10.2012, p. 675-678.

Research output: Contribution to journalArticle

Lebensburger, JD, Miller, ST, Howard, TH, Casella, JF, Brown, RC, Lu, M, Iyer, RV, Sarnaik, S, Rogers, ZR & Wang, WC 2012, 'Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study', Pediatric Blood and Cancer, vol. 59, no. 4, pp. 675-678. https://doi.org/10.1002/pbc.24037
Lebensburger, Jeffrey D. ; Miller, Scott T. ; Howard, Thomas H. ; Casella, James F ; Brown, R. Clark ; Lu, Ming ; Iyer, Rathi V. ; Sarnaik, Sharada ; Rogers, Zora R. ; Wang, Winfred C. / Influence of severity of anemia on clinical findings in infants with sickle cell anemia : Analyses from the BABY HUG study. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 4. pp. 675-678.
@article{291742fd170740859ddefc885489af3d,
title = "Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study",
abstract = "Background: Clinical complications of sickle cell anemia begin in infancy. BABY HUG (ClinicalTrials.gov, NCT00006400) was a NHLBI-NICHD supported randomized phase III placebo-controlled trial of hydroxyurea (HU) in infants (recruited at 9-18 months) unselected for clinical severity with sickle cell anemia. This secondary analysis of data from BABY HUG examines the influence of anemia on the incidence of sickle cell related complications, and the impact of hydroxyurea therapy in altering these events by comparing children with lower (75th percentile) hemoglobin concentrations at study entry. Procedure: Infants were categorized by: (1) age-adjusted hemoglobin quartiles as determined by higher (Hi) and lower (Lo) hemoglobin concentrations at study entry (9-12 months old: 10.0gm/dL; 12-18 months old: 9.9gm/dL) and (2) treatment arm (hydroxyurea or placebo). Four subgroups were created: placebo (PL) LoHb (n=25), PL HiHb (n=27), hydroxyurea (HU) LoHb (n=21), and HU HiHb (n=18). The primary and secondary endpoints of BABY HUG were analyzed by subgroup. Results: Infants with lower hemoglobin at baseline were more likely to have a higher incidence of clinical events (acute chest syndrome, pain crisis, fever) as well as higher TCD velocities and lower neuropsychological scores at study exit. Hydroxyurea reduced the incidence of these findings. Conclusion: Infants with more severe anemia are at risk for increased clinical events that may be prevented by early initiation of hydroxyurea. Pediatr Blood Cancer 2012;59:675-678.",
keywords = "Acute chest syndrome, Hydroxyurea, Pain, Renal, Sickle cell anemia, Spleen, Transcranial doppler",
author = "Lebensburger, {Jeffrey D.} and Miller, {Scott T.} and Howard, {Thomas H.} and Casella, {James F} and Brown, {R. Clark} and Ming Lu and Iyer, {Rathi V.} and Sharada Sarnaik and Rogers, {Zora R.} and Wang, {Winfred C.}",
year = "2012",
month = "10",
doi = "10.1002/pbc.24037",
language = "English (US)",
volume = "59",
pages = "675--678",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Influence of severity of anemia on clinical findings in infants with sickle cell anemia

T2 - Analyses from the BABY HUG study

AU - Lebensburger, Jeffrey D.

AU - Miller, Scott T.

AU - Howard, Thomas H.

AU - Casella, James F

AU - Brown, R. Clark

AU - Lu, Ming

AU - Iyer, Rathi V.

AU - Sarnaik, Sharada

AU - Rogers, Zora R.

AU - Wang, Winfred C.

PY - 2012/10

Y1 - 2012/10

N2 - Background: Clinical complications of sickle cell anemia begin in infancy. BABY HUG (ClinicalTrials.gov, NCT00006400) was a NHLBI-NICHD supported randomized phase III placebo-controlled trial of hydroxyurea (HU) in infants (recruited at 9-18 months) unselected for clinical severity with sickle cell anemia. This secondary analysis of data from BABY HUG examines the influence of anemia on the incidence of sickle cell related complications, and the impact of hydroxyurea therapy in altering these events by comparing children with lower (75th percentile) hemoglobin concentrations at study entry. Procedure: Infants were categorized by: (1) age-adjusted hemoglobin quartiles as determined by higher (Hi) and lower (Lo) hemoglobin concentrations at study entry (9-12 months old: 10.0gm/dL; 12-18 months old: 9.9gm/dL) and (2) treatment arm (hydroxyurea or placebo). Four subgroups were created: placebo (PL) LoHb (n=25), PL HiHb (n=27), hydroxyurea (HU) LoHb (n=21), and HU HiHb (n=18). The primary and secondary endpoints of BABY HUG were analyzed by subgroup. Results: Infants with lower hemoglobin at baseline were more likely to have a higher incidence of clinical events (acute chest syndrome, pain crisis, fever) as well as higher TCD velocities and lower neuropsychological scores at study exit. Hydroxyurea reduced the incidence of these findings. Conclusion: Infants with more severe anemia are at risk for increased clinical events that may be prevented by early initiation of hydroxyurea. Pediatr Blood Cancer 2012;59:675-678.

AB - Background: Clinical complications of sickle cell anemia begin in infancy. BABY HUG (ClinicalTrials.gov, NCT00006400) was a NHLBI-NICHD supported randomized phase III placebo-controlled trial of hydroxyurea (HU) in infants (recruited at 9-18 months) unselected for clinical severity with sickle cell anemia. This secondary analysis of data from BABY HUG examines the influence of anemia on the incidence of sickle cell related complications, and the impact of hydroxyurea therapy in altering these events by comparing children with lower (75th percentile) hemoglobin concentrations at study entry. Procedure: Infants were categorized by: (1) age-adjusted hemoglobin quartiles as determined by higher (Hi) and lower (Lo) hemoglobin concentrations at study entry (9-12 months old: 10.0gm/dL; 12-18 months old: 9.9gm/dL) and (2) treatment arm (hydroxyurea or placebo). Four subgroups were created: placebo (PL) LoHb (n=25), PL HiHb (n=27), hydroxyurea (HU) LoHb (n=21), and HU HiHb (n=18). The primary and secondary endpoints of BABY HUG were analyzed by subgroup. Results: Infants with lower hemoglobin at baseline were more likely to have a higher incidence of clinical events (acute chest syndrome, pain crisis, fever) as well as higher TCD velocities and lower neuropsychological scores at study exit. Hydroxyurea reduced the incidence of these findings. Conclusion: Infants with more severe anemia are at risk for increased clinical events that may be prevented by early initiation of hydroxyurea. Pediatr Blood Cancer 2012;59:675-678.

KW - Acute chest syndrome

KW - Hydroxyurea

KW - Pain

KW - Renal

KW - Sickle cell anemia

KW - Spleen

KW - Transcranial doppler

UR - http://www.scopus.com/inward/record.url?scp=84864942605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864942605&partnerID=8YFLogxK

U2 - 10.1002/pbc.24037

DO - 10.1002/pbc.24037

M3 - Article

C2 - 22190441

AN - SCOPUS:84864942605

VL - 59

SP - 675

EP - 678

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -